A RANDOMIZED TRIAL OF CLARITHROMYCIN AS PROPHYLAXIS AGAINST DISSEMINATED MYCOBACTERIUM-AVIUM COMPLEX INFECTION IN PATIENTS WITH ADVANCED ACQUIRED-IMMUNODEFICIENCY-SYNDROME
M. Pierce et al., A RANDOMIZED TRIAL OF CLARITHROMYCIN AS PROPHYLAXIS AGAINST DISSEMINATED MYCOBACTERIUM-AVIUM COMPLEX INFECTION IN PATIENTS WITH ADVANCED ACQUIRED-IMMUNODEFICIENCY-SYNDROME, The New England journal of medicine, 335(6), 1996, pp. 384-391
Background Disseminated infection with Mycobacterium avium complex is
the most common opportunistic infection in patients with advanced stag
es of the acquired immunodeficiency syndrome (AIDS). We studied the ef
ficacy and safety of prophylactic treatment with clarithromycin, a mac
rolide antibiotic. Methods We conducted a randomized, placebo-controll
ed, double-blind study of clarithromycin in patients with AIDS in the
United States and Europe. Entry criteria included blood cultures that
were negative for M. avium complex, a Karnofsky perform ance score of
50 or higher, a CD4 cell count of 100 or less per cubic millimeter, an
d a life expectancy of at least six months. Results After the first in
terim analysis, the study was stopped. M. avium complex infection deve
loped in 19 of the 333 patients (6 percent) assigned to clarith romyci
n and in 53 of the 334 (16 percent) assigned to placebo (adjusted haza
rd ratio, 0.31; 95 percent confidence interval, 0.18 to 0.53; P<0.001)
. During the follow-up period of about 10 months, 32 percent of the pa
tients in the clarithromycin group died and 41 percent of those in the
placebo group died (hazard ratio, 0.75; P=0.026). In the clarithromyc
in group, isolates from 11 of the 19 patients with M. avium complex in
fection were resistant to clarithromycin. Prophylaxis with clarithromy
cin was associated with an increased incidence of taste perversion (11
percent in the clarithromycin group vs. 2 percent in the placebo grou
p, P<0.001) and rectal disorders (8 percent vs. 3 percent, P=0.007); h
owever, the frequency of more severe adverse events was similar in the
two groups (7 percent and 6 percent, respectively). Conclusions In pa
tients with advanced AIDS, the prophylactic administration of clarithr
omycin is well tolerated, prevents M. avium complex infection, and red
uces mortality. (C) 1966, Massachusetts Medical Society.